sj-docx-1-tam-10.1177_17588359221105020 – Supplemental material for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

Lu, Shun; Cheng, Ying; Huang, Dingzhi; Sun, Yuping; Wu, Lin; Zhou, Chengzhi; Guo, Ye; Shao, Jingxin; Zhang, Wanli; Zhou, Jianying

Found an issue? Give us feedback

https://dx.doi.org/1...arrow_drop_down

https://dx.doi.org/10.25384/sa...

Other literature type . 2022

License: CC BY NC

Data sources: Datacite

https://dx.doi.org/10.25384/sa...

Other literature type . 2022

License: CC BY NC

Data sources: Datacite

sj-docx-1-tam-10.1177_17588359221105020 – Supplemental material for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

descriptionPublicationkeyboard_double_arrow_right Other literature type 01 Jan 2022Publisher:SAGE Journals

Authors: Lu, Shun; Cheng, Ying; Huang, Dingzhi; Sun, Yuping; Wu, Lin; Zhou, Chengzhi; Guo, Ye; +3 Authors

doi: 10.25384/sage.20406049.v1 , 10.25384/sage.20406049

sj-docx-1-tam-10.1177_17588359221105020 – Supplemental material for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

- Summary
- Subjects
- Related research
  (2)
- Metrics

Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221105020 for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321) by Shun Lu, Ying Cheng, Dingzhi Huang, Yuping Sun, Lin Wu, Chengzhi Zhou, Ye Guo, Jingxin Shao, Wanli Zhang and Jianying Zhou in Therapeutic Advances in Medical Oncology

Keywords

Oncology and Carcinogenesis not elsewhere classified, Aged Health Care, Respiratory Diseases, Pharmacology and Pharmaceutical Sciences not elsewhere classified

2 Research products, page 1 of 1

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average

Found an issue? Give us feedback

0

Average

Beta

SDGs Suggest

3. Good health

Beta

SDGs:

3. Good health,

Related to Research communities

Knowmad Institut

Cancer Research

Upload OA version

Are you the author of this publication? Upload your Open Access version to Zenodo!

It’s fast and easy, just two clicks!

uploadUpload now

sj-docx-1-tam-10.1177_17588359221105020 – Supplemental material for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

sj-docx-1-tam-10.1177_17588359221105020 – Supplemental material for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

2 Research products, page 1 of 1

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

sj-jpg-2-tam-10.1177_17588359221105020 – Supplemental material for Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)